Literature DB >> 12492184

Changing rates of Helicobacter pylori testing and treatment in patients with peptic ulcer disease.

Mihnea V Chiorean1, G Richard Locke, Alan R Zinsmeister, Cathy D Schleck, L Joseph Melton.   

Abstract

OBJECTIVES: The aim of this study was to identify temporal trends in the rate of Helicobacter pylori (H. pylori) testing, prevalence, and treatment among patients with peptic ulcer disease in Olmsted County, MN, from 1984 through 1997.
METHODS: All 3317 Olmsted County residents with a clinical diagnosis of peptic ulcer disease at the Mayo Clinic from 1984 through 1997 were identified. The complete medical records of an age-, sex-, and calendar year-stratified random sample were reviewed (n = 720); 298 patients (41%) had confirmed peptic ulcer disease. Changes in proportions of H. pylori testing, infection, and treatment over time were analyzed by logistic regression.
RESULTS: Of the 298 patients with confirmed peptic ulcer disease, 32% were tested for H. pylori; 36% were positive for infection, of whom 66% received antibiotic therapy. The rate of testing for H. pylori increased from 0% in 1984 to 96% in 1997, but the prevalence of infection did not change (36.4% vs 36.5%). The rate of treatment of those infected increased from 0% to 95%. By logistic regression, calendar year was associated with H. pylori testing and treatment but not infection. Recent use of nonsteroidal anti-inflammatory drugs was reported by 58% of patients, and 44% presented with GI bleeding.
CONCLUSIONS: Physicians' practice of testing and treating for H. pylori in patients with confirmed peptic ulcer disease has steadily increased over the past 14 yr. However, in our study, only 36% of these patients were infected with H. pylori, whereas the majority used nonsteroidal anti-inflammatory drugs (NSAIDs). Therefore, testing seems to be more appropriate than empiric treatment in patients with peptic ulcer disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12492184     DOI: 10.1111/j.1572-0241.2002.07119.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  3 in total

1.  Helicobacter pylori Eradication Therapy in Nonulcer Dyspepsia is Beneficial.

Authors:  Mohammed Q Khan
Journal:  Saudi J Gastroenterol       Date:  2008-04       Impact factor: 2.485

Review 2.  Interaction between Helicobacter pylori infection, nonsteroidal anti-inflammatory drugs and/or low-dose aspirin use: old question new insights.

Authors:  Carlos Sostres; Carla Jerusalen Gargallo; Angel Lanas
Journal:  World J Gastroenterol       Date:  2014-07-28       Impact factor: 5.742

Review 3.  Helicobacter pylori associated chronic gastritis, clinical syndromes, precancerous lesions, and pathogenesis of gastric cancer development.

Authors:  Jiro Watari; Nancy Chen; Peter S Amenta; Hirokazu Fukui; Tadayuki Oshima; Toshihiko Tomita; Hiroto Miwa; Kheng-Jim Lim; Kiron M Das
Journal:  World J Gastroenterol       Date:  2014-05-14       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.